Phase II Study of Combination Bortezomib and Panobinostat in Relapsed/Refractory PTCL or NK/T-Cell Lymphoma


Phase II Study of Combination Bortezomib and Panobinostat in Relapsed/Refractory PTCL or NK/T-Cell Lymphoma
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Brad S Kahl, MD (1/17/13)

Tan D et al. Bortezomib (BTZ) and panobinostat (PAN) combination is effective in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma (NKL) and maintenance treatment may be essential for sustained response. Proc ASH 2012;Abstract 3669.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.